MedDataX Logo

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

NCT ID: NCT00885612

Last Updated: 2010-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1114 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

NCT01758146

Breast Cancer
UNKNOWN PHASE3

The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer

NCT01080170

Breast Cancer
COMPLETED

Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor

NCT01765049

Invasive Breast Cancer Estrogen Receptor Positive Breast Cancer
ACTIVE_NOT_RECRUITING

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453

Healthy, no Evidence of Disease Lobular Breast Carcinoma in Situ
COMPLETED PHASE1

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621

Breast Cancer
ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Early Breast Cancer patients
* Postmenopausal Status
* patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion Criteria

* Advanced Breast Cancer patients(stage iii, iv)
* Patients who are hard to be analysed by limitation of chart record according to investigators discretion
* patients who already have been registered in this study
Minimum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JoonWoo Bahn, MD, PhD

Role: STUDY_DIRECTOR

AstraZeneca Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Cheonan, Chungcheongnam-do, South Korea

Site Status

Research Site

Chuncheon, Gangwon-do, South Korea

Site Status

Research Site

Goyang-si, Gyeonggi-do, South Korea

Site Status

Research Site

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Research Site

Pohang, Gyeongsangbuk-do, South Korea

Site Status

Research Site

Masan-si, Gyeongsangnam-do, South Korea

Site Status

Research Site

Anyang, , South Korea

Site Status

Research Site

Busan, , South Korea

Site Status

Research Site

Daegu, , South Korea

Site Status

Research Site

Daejeon, , South Korea

Site Status

Research Site

Gangneung, , South Korea

Site Status

Research Site

GuangJu, , South Korea

Site Status

Research Site

Gwangju, , South Korea

Site Status

Research Site

Incheon, , South Korea

Site Status

Research Site

Inchon, , South Korea

Site Status

Research Site

Jeonju, , South Korea

Site Status

Research Site

Junam, , South Korea

Site Status

Research Site

Koyang, , South Korea

Site Status

Research Site

Kyunggi, , South Korea

Site Status

Research Site

Pusan, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Seoul(Kangbuk), , South Korea

Site Status

Research Site

Seoul(Kangdong), , South Korea

Site Status

Research Site

Seoul(Kangnam), , South Korea

Site Status

Research Site

Seoul(Yeouido), , South Korea

Site Status

Research Site

Suwon, , South Korea

Site Status

Research Site

Ulsan, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OKR-DUM-2009/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
NCT01081509 COMPLETED
Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase
NCT03259711 COMPLETED
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
NCT06776458 RECRUITING
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
NCT01144572 COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women
NCT00090857 COMPLETED PHASE2
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
NCT06781762 RECRUITING
Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
NCT01275859 COMPLETED PHASE2
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
NCT00681928 COMPLETED
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
NCT01069211 UNKNOWN
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
NCT04541212 ACTIVE_NOT_RECRUITING
Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients
NCT02812277 UNKNOWN
Secondary Adjuvant Long Term Study With Arimidex
NCT00295620 COMPLETED PHASE3
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
NCT00516698 COMPLETED
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
NCT00638391 COMPLETED
Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment
NCT01596530 TERMINATED PHASE1
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
NCT00078832 COMPLETED PHASE3
HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer
NCT03111615 UNKNOWN PHASE4
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499 UNKNOWN PHASE3
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
NCT00357110 COMPLETED PHASE2
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215 TERMINATED PHASE2
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836 COMPLETED
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
NCT00719966 COMPLETED
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
NCT01298362 COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
NCT00238316 COMPLETED PHASE2
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632 NOT_YET_RECRUITING PHASE3